News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) Strikes $200.5 Million License Pact With Eli Lilly and Company (LLY)


8/29/2013 6:37:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

On August 26, 2013, ImmunoGen, Inc. (Nadaq: IMGN) entered into a license agreement with Eli Lilly and Company (NYSE: LLY) granting Lilly rights to use our maytansinoid-based Targeted Antibody Payload (TAP) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. This license was granted pursuant to the terms of an existing Multi-Target Agreement entered into by the Company and Lilly in 2011.

Help employers find you! Check out all the jobs and post your resume.

Read at Street Insider
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES